Is CNTA or DMRA more profitable?

Centessa Pharmaceuticals' return on equity of -60.37% beat Damora Therapeutics, Inc. Common Stock's return on equity. Company Net Margins Return on Equity Return on Assets Centessa Pharmaceuticals N/A -60.37% -44.17% Damora Therapeutics, Inc. Common Stock N/A -428.30% -114.62%

Which has higher valuation and earnings, COGT or DMRA?

Cogent Biosciences is trading at a lower price-to-earnings ratio than Damora Therapeutics, Inc. Common Stock, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cogent Biosciences N/A N/A -$328.94M -$2.17 N/A Damora Therapeutics, Inc. Common Stock N/A N/A -$209.84M -$5.58 N/A

Is COGT or DMRA more profitable?

Cogent Biosciences' return on equity of -104.27% beat Damora Therapeutics, Inc. Common Stock's return on equity. Company Net Margins Return on Equity Return on Assets Cogent Biosciences N/A -104.27% -54.64% Damora Therapeutics, Inc. Common Stock N/A -428.30% -114.62%

Which has preferable valuation and earnings, DMRA or BLTE?

Belite Bio is trading at a lower price-to-earnings ratio than Damora Therapeutics, Inc. Common Stock, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Damora Therapeutics, Inc. Common Stock N/A N/A -$209.84M -$5.58 N/A Belite Bio N/A N/A -$77.61M -$2.53 N/A

Is DMRA or BLTE more profitable?

Belite Bio's return on equity of -13.14% beat Damora Therapeutics, Inc. Common Stock's return on equity. Company Net Margins Return on Equity Return on Assets Damora Therapeutics, Inc. Common Stock N/A -428.30% -114.62% Belite Bio N/A -13.14% -12.88%

Damora Therapeutics, Inc. Common Stock (DMRA) Competitors

$20.15 -0.81 (-3.86%)

As of 04:00 PM Eastern

Compare

DMRA vs. PTGX, RYTM, CNTA, COGT, and BLTE

Should you buy Damora Therapeutics, Inc. Common Stock stock or one of its competitors? MarketBeat compares Damora Therapeutics, Inc. Common Stock with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Damora Therapeutics, Inc. Common Stock include Protagonist Therapeutics (PTGX), Rhythm Pharmaceuticals (RYTM), Centessa Pharmaceuticals (CNTA), Cogent Biosciences (COGT), and Belite Bio (BLTE). These companies are all part of the "pharmaceutical products" industry.

How does Damora Therapeutics, Inc. Common Stock compare to Protagonist Therapeutics?

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) and Protagonist Therapeutics (NASDAQ:PTGX) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, risk, media sentiment, valuation, institutional ownership, profitability, analyst recommendations and dividends.

Damora Therapeutics, Inc. Common Stock has a beta of 1.46, indicating that its stock price is 46% more volatile than the broader market. Comparatively, Protagonist Therapeutics has a beta of 1.85, indicating that its stock price is 85% more volatile than the broader market.

In the previous week, Protagonist Therapeutics had 3 more articles in the media than Damora Therapeutics, Inc. Common Stock. MarketBeat recorded 5 mentions for Protagonist Therapeutics and 2 mentions for Damora Therapeutics, Inc. Common Stock. Damora Therapeutics, Inc. Common Stock's average media sentiment score of 1.43 beat Protagonist Therapeutics' score of 1.23 indicating that Damora Therapeutics, Inc. Common Stock is being referred to more favorably in the media.

Company	Overall Sentiment
Damora Therapeutics, Inc. Common Stock	Positive
Protagonist Therapeutics	Positive

Damora Therapeutics, Inc. Common Stock presently has a consensus target price of $42.00, suggesting a potential upside of 108.44%. Protagonist Therapeutics has a consensus target price of $115.21, suggesting a potential upside of 8.93%. Given Damora Therapeutics, Inc. Common Stock's stronger consensus rating and higher possible upside, equities analysts clearly believe Damora Therapeutics, Inc. Common Stock is more favorable than Protagonist Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Damora Therapeutics, Inc. Common Stock	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.90
Protagonist Therapeutics	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.88

Protagonist Therapeutics has higher revenue and earnings than Damora Therapeutics, Inc. Common Stock. Protagonist Therapeutics is trading at a lower price-to-earnings ratio than Damora Therapeutics, Inc. Common Stock, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Damora Therapeutics, Inc. Common Stock	N/A	N/A	-$209.84M	-$5.58	N/A
Protagonist Therapeutics	$46.02M	147.81	-$130.15M	-$1.81	N/A

Damora Therapeutics, Inc. Common Stock has a net margin of 0.00% compared to Protagonist Therapeutics' net margin of -154.88%. Protagonist Therapeutics' return on equity of -17.76% beat Damora Therapeutics, Inc. Common Stock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Damora Therapeutics, Inc. Common Stock	N/A	-428.30%	-114.62%
Protagonist Therapeutics	-154.88%	-17.76%	-16.47%

14.2% of Damora Therapeutics, Inc. Common Stock shares are held by institutional investors. Comparatively, 98.6% of Protagonist Therapeutics shares are held by institutional investors. 0.4% of Damora Therapeutics, Inc. Common Stock shares are held by insiders. Comparatively, 5.2% of Protagonist Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Protagonist Therapeutics beats Damora Therapeutics, Inc. Common Stock on 10 of the 16 factors compared between the two stocks.

How does Damora Therapeutics, Inc. Common Stock compare to Rhythm Pharmaceuticals?

Rhythm Pharmaceuticals (NASDAQ:RYTM) and Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, risk, profitability, media sentiment, valuation, dividends, institutional ownership and analyst recommendations.

Rhythm Pharmaceuticals currently has a consensus price target of $131.81, suggesting a potential upside of 53.79%. Damora Therapeutics, Inc. Common Stock has a consensus price target of $42.00, suggesting a potential upside of 108.44%. Given Damora Therapeutics, Inc. Common Stock's stronger consensus rating and higher probable upside, analysts plainly believe Damora Therapeutics, Inc. Common Stock is more favorable than Rhythm Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rhythm Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	2.83
Damora Therapeutics, Inc. Common Stock	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.90

Damora Therapeutics, Inc. Common Stock has a net margin of 0.00% compared to Rhythm Pharmaceuticals' net margin of -93.33%. Rhythm Pharmaceuticals' return on equity of -203.25% beat Damora Therapeutics, Inc. Common Stock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rhythm Pharmaceuticals	-93.33%	-203.25%	-44.99%
Damora Therapeutics, Inc. Common Stock	N/A	-428.30%	-114.62%

Rhythm Pharmaceuticals has higher revenue and earnings than Damora Therapeutics, Inc. Common Stock. Rhythm Pharmaceuticals is trading at a lower price-to-earnings ratio than Damora Therapeutics, Inc. Common Stock, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rhythm Pharmaceuticals	$189.76M	30.95	-$196.54M	-$3.13	N/A
Damora Therapeutics, Inc. Common Stock	N/A	N/A	-$209.84M	-$5.58	N/A

Rhythm Pharmaceuticals has a beta of 1.91, suggesting that its stock price is 91% more volatile than the broader market. Comparatively, Damora Therapeutics, Inc. Common Stock has a beta of 1.46, suggesting that its stock price is 46% more volatile than the broader market.

In the previous week, Rhythm Pharmaceuticals had 1 more articles in the media than Damora Therapeutics, Inc. Common Stock. MarketBeat recorded 3 mentions for Rhythm Pharmaceuticals and 2 mentions for Damora Therapeutics, Inc. Common Stock. Damora Therapeutics, Inc. Common Stock's average media sentiment score of 1.43 beat Rhythm Pharmaceuticals' score of 0.47 indicating that Damora Therapeutics, Inc. Common Stock is being referred to more favorably in the news media.

Company	Overall Sentiment
Rhythm Pharmaceuticals	Neutral
Damora Therapeutics, Inc. Common Stock	Positive

14.2% of Damora Therapeutics, Inc. Common Stock shares are owned by institutional investors. 5.9% of Rhythm Pharmaceuticals shares are owned by insiders. Comparatively, 0.4% of Damora Therapeutics, Inc. Common Stock shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Rhythm Pharmaceuticals beats Damora Therapeutics, Inc. Common Stock on 9 of the 16 factors compared between the two stocks.

How does Damora Therapeutics, Inc. Common Stock compare to Centessa Pharmaceuticals?

Centessa Pharmaceuticals (NASDAQ:CNTA) and Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, media sentiment, profitability, earnings, institutional ownership, risk, dividends and valuation.

Centessa Pharmaceuticals has higher revenue and earnings than Damora Therapeutics, Inc. Common Stock. Centessa Pharmaceuticals is trading at a lower price-to-earnings ratio than Damora Therapeutics, Inc. Common Stock, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Centessa Pharmaceuticals	$15M	394.86	-$197.53M	-$1.79	N/A
Damora Therapeutics, Inc. Common Stock	N/A	N/A	-$209.84M	-$5.58	N/A

82.0% of Centessa Pharmaceuticals shares are held by institutional investors. Comparatively, 14.2% of Damora Therapeutics, Inc. Common Stock shares are held by institutional investors. 4.1% of Centessa Pharmaceuticals shares are held by company insiders. Comparatively, 0.4% of Damora Therapeutics, Inc. Common Stock shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Centessa Pharmaceuticals currently has a consensus price target of $41.33, indicating a potential upside of 4.14%. Damora Therapeutics, Inc. Common Stock has a consensus price target of $42.00, indicating a potential upside of 108.44%. Given Damora Therapeutics, Inc. Common Stock's stronger consensus rating and higher probable upside, analysts clearly believe Damora Therapeutics, Inc. Common Stock is more favorable than Centessa Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Centessa Pharmaceuticals	1 Sell rating(s)	9 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.21
Damora Therapeutics, Inc. Common Stock	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.90

In the previous week, Centessa Pharmaceuticals had 2 more articles in the media than Damora Therapeutics, Inc. Common Stock. MarketBeat recorded 4 mentions for Centessa Pharmaceuticals and 2 mentions for Damora Therapeutics, Inc. Common Stock. Damora Therapeutics, Inc. Common Stock's average media sentiment score of 1.43 beat Centessa Pharmaceuticals' score of 1.33 indicating that Damora Therapeutics, Inc. Common Stock is being referred to more favorably in the news media.

Company	Overall Sentiment
Centessa Pharmaceuticals	Positive
Damora Therapeutics, Inc. Common Stock	Positive

Centessa Pharmaceuticals' return on equity of -60.37% beat Damora Therapeutics, Inc. Common Stock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Centessa Pharmaceuticals	N/A	-60.37%	-44.17%
Damora Therapeutics, Inc. Common Stock	N/A	-428.30%	-114.62%

Centessa Pharmaceuticals has a beta of 1.11, suggesting that its stock price is 11% more volatile than the broader market. Comparatively, Damora Therapeutics, Inc. Common Stock has a beta of 1.46, suggesting that its stock price is 46% more volatile than the broader market.

Summary

Centessa Pharmaceuticals beats Damora Therapeutics, Inc. Common Stock on 8 of the 15 factors compared between the two stocks.

How does Damora Therapeutics, Inc. Common Stock compare to Cogent Biosciences?

Cogent Biosciences (NASDAQ:COGT) and Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, profitability, earnings, dividends, institutional ownership, media sentiment, analyst recommendations and valuation.

Cogent Biosciences currently has a consensus target price of $43.73, indicating a potential upside of 39.35%. Damora Therapeutics, Inc. Common Stock has a consensus target price of $42.00, indicating a potential upside of 108.44%. Given Damora Therapeutics, Inc. Common Stock's stronger consensus rating and higher probable upside, analysts clearly believe Damora Therapeutics, Inc. Common Stock is more favorable than Cogent Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cogent Biosciences	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.86
Damora Therapeutics, Inc. Common Stock	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.90

In the previous week, Cogent Biosciences had 3 more articles in the media than Damora Therapeutics, Inc. Common Stock. MarketBeat recorded 5 mentions for Cogent Biosciences and 2 mentions for Damora Therapeutics, Inc. Common Stock. Damora Therapeutics, Inc. Common Stock's average media sentiment score of 1.43 beat Cogent Biosciences' score of 0.87 indicating that Damora Therapeutics, Inc. Common Stock is being referred to more favorably in the news media.

Company	Overall Sentiment
Cogent Biosciences	Positive
Damora Therapeutics, Inc. Common Stock	Positive

Cogent Biosciences' return on equity of -104.27% beat Damora Therapeutics, Inc. Common Stock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cogent Biosciences	N/A	-104.27%	-54.64%
Damora Therapeutics, Inc. Common Stock	N/A	-428.30%	-114.62%

Cogent Biosciences is trading at a lower price-to-earnings ratio than Damora Therapeutics, Inc. Common Stock, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cogent Biosciences	N/A	N/A	-$328.94M	-$2.17	N/A
Damora Therapeutics, Inc. Common Stock	N/A	N/A	-$209.84M	-$5.58	N/A

Cogent Biosciences has a beta of 0.34, suggesting that its stock price is 66% less volatile than the broader market. Comparatively, Damora Therapeutics, Inc. Common Stock has a beta of 1.46, suggesting that its stock price is 46% more volatile than the broader market.

14.2% of Damora Therapeutics, Inc. Common Stock shares are owned by institutional investors. 6.6% of Cogent Biosciences shares are owned by insiders. Comparatively, 0.4% of Damora Therapeutics, Inc. Common Stock shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Damora Therapeutics, Inc. Common Stock beats Cogent Biosciences on 7 of the 13 factors compared between the two stocks.

How does Damora Therapeutics, Inc. Common Stock compare to Belite Bio?

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) and Belite Bio (NASDAQ:BLTE) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, valuation, analyst recommendations, profitability, dividends, institutional ownership, risk and earnings.

14.2% of Damora Therapeutics, Inc. Common Stock shares are owned by institutional investors. Comparatively, 0.5% of Belite Bio shares are owned by institutional investors. 0.4% of Damora Therapeutics, Inc. Common Stock shares are owned by company insiders. Comparatively, 13.3% of Belite Bio shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Belite Bio's return on equity of -13.14% beat Damora Therapeutics, Inc. Common Stock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Damora Therapeutics, Inc. Common Stock	N/A	-428.30%	-114.62%
Belite Bio	N/A	-13.14%	-12.88%

Belite Bio is trading at a lower price-to-earnings ratio than Damora Therapeutics, Inc. Common Stock, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Damora Therapeutics, Inc. Common Stock	N/A	N/A	-$209.84M	-$5.58	N/A
Belite Bio	N/A	N/A	-$77.61M	-$2.53	N/A

Damora Therapeutics, Inc. Common Stock presently has a consensus target price of $42.00, suggesting a potential upside of 108.44%. Belite Bio has a consensus target price of $203.00, suggesting a potential upside of 48.59%. Given Damora Therapeutics, Inc. Common Stock's stronger consensus rating and higher probable upside, analysts plainly believe Damora Therapeutics, Inc. Common Stock is more favorable than Belite Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Damora Therapeutics, Inc. Common Stock	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.90
Belite Bio	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

Damora Therapeutics, Inc. Common Stock has a beta of 1.46, suggesting that its stock price is 46% more volatile than the broader market. Comparatively, Belite Bio has a beta of -1.24, suggesting that its stock price is 224% less volatile than the broader market.

In the previous week, Damora Therapeutics, Inc. Common Stock and Damora Therapeutics, Inc. Common Stock both had 2 articles in the media. Damora Therapeutics, Inc. Common Stock's average media sentiment score of 1.43 beat Belite Bio's score of 0.93 indicating that Damora Therapeutics, Inc. Common Stock is being referred to more favorably in the media.

Company	Overall Sentiment
Damora Therapeutics, Inc. Common Stock	Positive
Belite Bio	Positive

Summary

Damora Therapeutics, Inc. Common Stock beats Belite Bio on 7 of the 12 factors compared between the two stocks.

Get Damora Therapeutics, Inc. Common Stock News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DMRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

DMRA vs. The Competition

Export

Metric	Damora Therapeutics, Inc. Common Stock	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.24B	$3.28B	$6.41B	$11.71B
Dividend Yield	N/A	2.33%	2.67%	5.55%
P/E Ratio	-3.61	18.99	24.46	23.62
Price / Sales	N/A	290.48	500.50	105.26
Price / Cash	N/A	118.24	42.36	56.09
Price / Book	-0.18	8.00	10.43	6.70
Net Income	-$209.84M	$23.89M	$3.56B	$337.26M
7 Day Performance	-9.92%	-3.49%	-1.39%	-1.41%
1 Month Performance	-16.60%	1.03%	0.86%	1.15%
1 Year Performance	499.70%	34.39%	19.42%	22.61%

Damora Therapeutics, Inc. Common Stock Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
DMRA Damora Therapeutics, Inc. Common Stock	2.7223 of 5 stars	$20.15 -3.9%	$42.00 +108.4%	+537.1%	$1.24B	N/A	N/A	40	Positive News Analyst Forecast
PTGX Protagonist Therapeutics	1.8501 of 5 stars	$93.19 -1.8%	$115.21 +23.6%	+90.1%	$6.10B	$46.02M	N/A	120	Positive News
RYTM Rhythm Pharmaceuticals	2.7876 of 5 stars	$84.35 -4.0%	$131.81 +56.3%	+31.7%	$6.02B	$189.76M	N/A	140
CNTA Centessa Pharmaceuticals	1.7004 of 5 stars	$39.90 +0.1%	$41.33 +3.6%	+233.0%	$5.95B	$15M	N/A	200	News Coverage Positive News
COGT Cogent Biosciences	2.9428 of 5 stars	$32.76 -5.9%	$43.73 +33.5%	+363.5%	$5.95B	N/A	N/A	80	News Coverage High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:DMRA) was last updated on 6/10/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Damora Therapeutics, Inc. Common Stock (DMRA) Competitors

DMRA vs. PTGX, RYTM, CNTA, COGT, and BLTE

How does Damora Therapeutics, Inc. Common Stock compare to Protagonist Therapeutics?

Summary

How does Damora Therapeutics, Inc. Common Stock compare to Rhythm Pharmaceuticals?

Summary

How does Damora Therapeutics, Inc. Common Stock compare to Centessa Pharmaceuticals?

Summary

How does Damora Therapeutics, Inc. Common Stock compare to Cogent Biosciences?

Summary

How does Damora Therapeutics, Inc. Common Stock compare to Belite Bio?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DMRA vs. The Competition

Damora Therapeutics, Inc. Common Stock Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Damora Therapeutics, Inc. Common Stock (DMRA) Competitors

DMRA vs. PTGX, RYTM, CNTA, COGT, and BLTE

How does Damora Therapeutics, Inc. Common Stock compare to Protagonist Therapeutics?

Which has more volatility & risk, DMRA or PTGX?

Does the media favor DMRA or PTGX?

Do analysts recommend DMRA or PTGX?

Which has stronger valuation & earnings, DMRA or PTGX?

Is DMRA or PTGX more profitable?

Do institutionals & insiders hold more shares of DMRA or PTGX?

Summary

How does Damora Therapeutics, Inc. Common Stock compare to Rhythm Pharmaceuticals?

Do analysts prefer RYTM or DMRA?

Is RYTM or DMRA more profitable?

Which has better earnings and valuation, RYTM or DMRA?

Which has more risk & volatility, RYTM or DMRA?

Does the media prefer RYTM or DMRA?

Do institutionals & insiders hold more shares of RYTM or DMRA?

Summary

How does Damora Therapeutics, Inc. Common Stock compare to Centessa Pharmaceuticals?

Which has stronger earnings & valuation, CNTA or DMRA?

Do insiders and institutionals believe in CNTA or DMRA?

Do analysts recommend CNTA or DMRA?

Does the media favor CNTA or DMRA?

Is CNTA or DMRA more profitable?

Which has more risk & volatility, CNTA or DMRA?

Summary

How does Damora Therapeutics, Inc. Common Stock compare to Cogent Biosciences?

Do analysts rate COGT or DMRA?

Does the media refer more to COGT or DMRA?

Is COGT or DMRA more profitable?

Which has higher valuation and earnings, COGT or DMRA?

Which has more risk and volatility, COGT or DMRA?

Do institutionals and insiders believe in COGT or DMRA?

Summary

How does Damora Therapeutics, Inc. Common Stock compare to Belite Bio?

Do institutionals & insiders hold more shares of DMRA or BLTE?

Is DMRA or BLTE more profitable?

Which has preferable valuation and earnings, DMRA or BLTE?

Do analysts prefer DMRA or BLTE?

Which has more volatility & risk, DMRA or BLTE?

Does the media favor DMRA or BLTE?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DMRA vs. The Competition

Damora Therapeutics, Inc. Common Stock Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools